The first biologic was approved in 1982, and since then, have become one of the fastest-growing segments of the US pharmaceutical market. Biologics are complex therapies used to treat a wide variety of conditions – conditions that are often untreatable by any other drug – and physicians should be up to speed on these four classes of biologic agents, which are used to treat cancer or inflammatory disease.

According to the American Institute for Cancer Research, a diet filled with a variety of vegetables, fruits, whole grains, beans, and other plant foods helps lower risk for many cancers, thanks to their bioactive compounds. Things like bergamottin. Isothiocyanates. Polyphenols. Continue reading to discover five foods that have the potential to fight cancer, including pancreatic, skin, and more.

“You are what you eat,” right? Well, according to the National Institute on Aging (NIA), what you put into your mouth could be influencing your cognitive health and performance. A healthy diet of fruits, vegetables, lean meats, fish, poultry, low-fat/nonfat dairy products, and whole grains is essential, as is limiting fats, sugars, and salt. But here is the best of the best when it comes to boosting the brain.

The approval of the new cetuximab (Erbitux) dosage – 500 mg/m2 as a two-hour IV infusion every two weeks – was based on population pharmacokinetic (PK) modeling analyses and provides an alternative option to the previously approved weekly dose. Cetuximab can be dosed alone or in combination with chemotherapy.

In this Original Investigation from JAMA, the authors attempt to discover how the landscape of cancer incidences and deaths will change in the next two decades. The findings suggest marked changes in the landscape of cancer incidence and deaths by 2040, emphasizing the importance of cancer screening, early detection, and prevention to guide research, health care, and health policy efforts.

Although the MYSTIC phase 3 clinical trial examining durvalumab therapy for non–small-cell lung cancer (NSCLC) did not meet its primary end points – overall survival (OS) and progression-free survival (PFS) – it did show a numerically reduced risk for death with durvalumab (Imfinzi) versus chemotherapy in patients with PD-L1 expression on ≥25% of tumor cells.